ARTICLE
14 February 2018

Massachusetts' New U.S. Attorney Vows To Continue Pressure On Drug Makers And Patient Assistance Programs

FL
FisherBroyles LLP

Contributor

FisherBroyles LLP
Readers may recall our alert from November 2017, "Patient Assistance Charity Loses Protection from Kickback Liability – Office of Inspector General Revokes Advisory Opinion" in which we relayed the story of Caring Voice Coalition (CVC), a patient assistance program formed to help patients afford expensive prescription drugs by funding health insurance copayments
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Readers may recall our alert from November 2017, " Patient Assistance Charity Loses Protection from Kickback Liability – Office of Inspector General Revokes Advisory Opinion" in which we relayed the story of Caring Voice Coalition (CVC), a patient assistance program formed to help patients afford expensive prescription drugs by funding health insurance copayments. CVC, like many other patient assistance programs, is funded almost entirely by donations from drug makers. Given the primary source of their funding, the programs rely on government protection from Kickback liability, which is generally granted so long as the programs demonstrate that a bona fide charitable organization is interposed between the drug manufacturers and the recipients of aid.

Recent investigations in Massachusetts however, have revealed that a number of drug makers and patient assistance programs, much like CVC, are skirting the rules and, in the words of Massachusetts' new U.S. Attorney Andrew Lelling, "distort[ing] the pay structure for Medicaid" by illegally giving money to patient assistance programs with the expectation that it would later be paid back through various shady mechanisms. The U.S. Attorneys office in Massachusetts, in investigations all launched prior to Lelling's appointment, has ongoing probes involving Pfizer, Inc. and Johnson & Johnson. United Therapeutics Corp. recently settled similar allegations for $210 million, while Aegerion Pharmaceuticals is currently engaged in settlement discussions.

Lelling has publicly stated that he plans to continue to keep the pressure on both drug makers and patient assistance charities that are involved in "crooked" donations.

"It's unfortunate that the drug companies have put us in this position, but it is something that we're going to fix, and we try to fix it keeping in mind that there are people who need these drugs...who need to be able to afford these drugs," said Lelling.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More